

## Disclosures

### Personal Commercial (51)

| Company Name                     | Relationship Category       | Compensation Level       | Topic Area(s)                      |
|----------------------------------|-----------------------------|--------------------------|------------------------------------|
| <i>Self</i>                      |                             |                          |                                    |
| Abbott Laboratories              | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Alnylam                          | Research/Research Grants    | Significant (>= \$5,000) | Other                              |
| Alnylam                          | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Amgen Inc.                       | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Analog Medical Devices           | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Anthos Therapeutics              | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Vascular Medicine                  |
| Anumana/nference                 | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| AstraZeneca Pharmaceuticals      | Research/Research Grants    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| AstraZeneca Pharmaceuticals      | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Avalyn Pharma                    | Research/Research Grants    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Avania Clinical Research         | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Avidity Biopharma                | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Axon Therapeutics                | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Baim Clinical Research Institute | Other - Adjudicator for CEC | Significant (>= \$5,000) | General Cardiology                 |
| Bayer Healthcare Pharmaceuticals | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Bayer Healthcare Pharmaceuticals | Research/Research Grants    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Biofourmis                       | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Boston Scientific                | Consultant Fees/Honoraria   | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| ClinChoice                       | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Colorado Prevention Center       | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Corsera Health                   | Consultant Fees/Honoraria   | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| CVS Caremark                     | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Cytokinetics                     | Consultant Fees/Honoraria   | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| DevPro Biopharma                 | Research/Research Grants    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Duke Clinical Research Institute | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Edwards Lifesciences             | Consultant Fees/Honoraria   | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Eli Lilly and Company            | Consultant Fees/Honoraria   | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Endotronix                       | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| FIRE1 Foundry                    | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| GlaxoSmithKline                  | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Other                              |
| ICON Clinical Research           | Consultant Fees/Honoraria   | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| iRhythm Technologies             | Consultant Fees/Honoraria   | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Medpace                          | Consultant Fees/Honoraria   | Significant (>= \$5,000) | General Cardiology                 |
| Medtronic                        | Consultant Fees/Honoraria   | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |

| Company Name                         | Relationship Category                        | Compensation Level       | Topic Area(s)                                      |
|--------------------------------------|--|--------------------------|--|
| Merck & Co., Inc.                    | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | <a href="#">Heart Failure and Cardiomyopathies</a> |
| New Amsterdam                        | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | <a href="#">General Cardiology</a>                 |
| Novartis Corporation                 | Research/Research Grants                     | Significant (>= \$5,000) | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Novartis Corporation                 | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Parexel                              | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Pfizer Inc                           | Research/Research Grants<br>‡ GARDEN TIMI-75 | None (\$0)               | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Pharmacosmos                         | Research/Research Grants                     | Significant (>= \$5,000) | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Regeneron                            | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | <a href="#">Heart Failure and Cardiomyopathies</a> |
| River2Renal                          | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Roche                                | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | <a href="#">General Cardiology</a>                 |
| scPharma                             | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Stanford Clinical Research Institute | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Teva                                 | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | <a href="#">Heart Failure and Cardiomyopathies</a> |
| TIMI Study Group                     | Other - Adjudication for CEC                 | Significant (>= \$5,000) | <a href="#">General Cardiology</a>                 |
| Vectorious Medical Technologies      | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Verve Therapeutics                   | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | <a href="#">Heart Failure and Cardiomyopathies</a> |
| Volta medical                        | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | <a href="#">Heart Failure and Cardiomyopathies</a> |

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Entity Name | Relationship Category                    | Compensation Level | Topic Area(s)                                      |
|----------------------------|--|--------------------|--|
| <b>Self</b>                |  |                    |  |
| DTX Plus, Inc              | Ownership Interest/Partnership/Principal | Modest (< \$5,000) | <a href="#">Heart Failure and Cardiomyopathies</a> |

## Clinical Trial Enroller (1)

| Trial Name | Trial Sponsor     | Trial Funding Source |
|------------|-------------------|----------------------|
| ALLAY-HF   | Alleviant Medical |                      |

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (3)

| Year        | Case Title                     | Represented | Description  | Compensation             |
|-------------|--------------------------------|-------------|--|--------------------------|
| <b>Self</b> |                                |             |  |                          |
| 2026        | Endocarditis                   | Plaintiff   | Delay in care related to failure to diagnose endocarditis                        | Significant (>= \$5,000) |
| 2019        | Cardiomyopathy                 | Defendant   | Failure to diagnose and treat hemochromatosis involving the heart                | Modest (< \$5,000)       |
| 2018        | Out of Hospital Cardiac Arrest | Plaintiff   | Failure to defibrillate patient with available AED during out of hospital arrest | Modest (< \$5,000)       |

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 4/6/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 4/6/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 4/6/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.